Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
30,949,779
-
Share change
-
+1,642,302
-
Total reported value
-
$384,461,374
-
Put/Call ratio
-
13%
-
Price per share
-
$12.42
-
Number of holders
-
99
-
Value change
-
+$12,666,882
-
Number of buys
-
44
-
Number of sells
-
53
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2017
As of 30 Jun 2017 Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) had 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 30,949,779 shares of stock of the company.
Largest 10 holders included FMR LLC, BlackRock Inc., VANGUARD GROUP INC, BB BIOTECH AG, WASATCH ADVISORS INC, CITADEL ADVISORS LLC, STATE STREET CORP, Hillhouse Capital Management, Ltd., BANK OF AMERICA CORP /DE/, and RHENMAN & PARTNERS ASSET MANAGEMENT AB.
This table shows 99 institutional shareholders of the security as of 30 Jun 2017.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.